Coronavirus: A Disease of the Haemoglobin? Suggested Therapeutic Approaches
The pathophysiology of the coronavirus infection is not yet fully understood. Several theories have been developed from the acute respiratory distress syndrome to antiphospholipid antibody syndrome to vascular thrombosis. It is in this context that we propose through brainstorming some proposals for the therapeutic management based on secondary haemoglobin damage by COVID-19.
Keywords: coronavirus - haemoglobin - chloroquine - pathophysiology
(2) Pariente, R. So-called atypical coronavirus pneumopathies. CME-Pneumology, 2004; 1(1):3-6.
(3) Beck, B. R., Shin, B., Choi, Y., Park, S., & Kang, K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model. bioRxiv. 2020.
(4) Colson, P., Rolain, J. M., & Raoult, D. Chloroquine for the 2019 novel coronavirus. Int J Antimicrob Agents. 2020.
(5) World Health Organization, O. Clinical management of severe acute respiratory infection when infection with a new coronavirus (nCoV) is suspected: interim guidelines, 25 January 2020 (No. WHO/nCoV/Clinical/2020.2). World Health Organization. 2020.
(6) Pariente, R. So-called atypical coronavirus pneumopathies. CME-Pneumology, 2004; 1(1):3-6.
(7) Liu, W., & Li, H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism.
(8) Storz, J., Stine, L., Liem, A., & Anderson, G. A. Coronavirus isolation from nasal swab samples in cattle with signs of respiratory tract disease after shipping. Journal of the American Veterinary Medical Association, 1996; 208(9):1452-1455.
(9) Mungthin, M., Bray, P. G., Ridley, R. G., & Ward, S. A. Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. Antimicrobial agents and chemotherapy, 1998; 42(11):2973-2977.
(10) Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care. 2020.
(11) Wu, C., Chen, X., Cai, Y., Zhou, X., Xu, S., Huang, H., ... & Song, J. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine. 2020.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).